Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
Roland J. Fuchs(Kantonsspital Aarau), Katharina Kohlbrenner(Heidelberg University), Frank Stegelmann(University Hospital Ulm), Karsten Spiekermann(German Cancer Research Center), Susanne Saußele(University of Mannheim), Rüdiger Hehlmann(Heidelberg University), Jolanta Dengler(Heidelberg University), Birgit Spieß(Heidelberg University), Dietrich W. Beelen(Essen University Hospital), Claudia Haferlach(Munich Leukemia Laboratory (Germany)), Tim H. Brümmendorf(Heidelberg University), Wolfgang E. Berdel(University Hospital Münster), Sébastien Rinaldetti(Heidelberg University), Brigitte Schlegelberger(Heidelberg University), M-E Goebeler(Universitätsklinikum Würzburg), Leopold Balleisen(Evangelisches Krankenhaus Hamm), Christiane Falge(Nuremberg Hospital), Andreas Neubauer(RWTH Aachen University), M. Pfreundschuh(Saarland University), Jiřı́ Mayer(Masaryk University), Bernd Hertenstein(San Antonio College), Wolfgang Seifarth(Heidelberg University), Cornelius F. Waller(University Medical Center Freiburg), Marcus Müller(Heidelberg University), Hartmut Link(Medizinische Hochschule Hannover), Mathias Hänel(Klinikum Chemnitz), Michael Kneba(Universitäts Hautklinik Kiel), Hans‐Jochem Kolb(Deutsche Klinik für Diagnostik), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Anthony D. Ho(Heidelberg University), Michael Lauseker(Zimmer Biomet (Germany)), Aloïs Gratwohl, Andreas Burchert(Philipps University of Marburg), Claus-Henning Köhne(Klinikum Oldenburg), Stefan W. Krause(Universitätsklinikum Erlangen), Matthias Edinger(University Hospital Regensburg), Stephan Kremers, Lothar Müller, Dominik Heim(University Hospital of Basel), Gabriela M. Baerlocher(Terry Fox Research Institute), Ulrike Proetel(Heidelberg University), Sabine Jeromin(Heidelberg University), Dieter K. Hossfeld(Universität Hamburg), Lothar Kanz(University of Freiburg), C. Nerl(University Hospital of Basel), Martin Bentz(Städtisches Klinikum Karlsruhe), H. W. Lindemann(University Medical Center Freiburg), Alice Fabarius(Heidelberg University), Astghik Voskanyan(Heidelberg University)
Cited by 339
Related Papers
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k